Sunesis Pharmaceuticals Inc. (SNSS)’s Financial Results Comparing With Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)

Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sunesis Pharmaceuticals Inc. N/A 0.00 25.20M -0.75 0.00
Conatus Pharmaceuticals Inc. 30.87M 0.83 17.74M -0.57 0.00

In table 1 we can see Sunesis Pharmaceuticals Inc. and Conatus Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Sunesis Pharmaceuticals Inc. 0.00% 235.2% -123.9%
Conatus Pharmaceuticals Inc. -57.47% -81% -32.8%

Volatility and Risk

Sunesis Pharmaceuticals Inc. is 170.00% more volatile than Standard and Poor’s 500 due to its 2.7 beta. Conatus Pharmaceuticals Inc.’s 3.06 beta is the reason why it is 206.00% more volatile than Standard and Poor’s 500.

Liquidity

Sunesis Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 1.3 and 1.3 respectively. The Current Ratio and Quick Ratio of its competitor Conatus Pharmaceuticals Inc. are 2.4 and 2.4 respectively. Conatus Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Sunesis Pharmaceuticals Inc.

Analyst Ratings

Sunesis Pharmaceuticals Inc. and Conatus Pharmaceuticals Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sunesis Pharmaceuticals Inc. 0 1 1 2.50
Conatus Pharmaceuticals Inc. 0 1 0 2.00

Sunesis Pharmaceuticals Inc.’s average target price is $3.25, while its potential upside is 261.11%. On the other hand, Conatus Pharmaceuticals Inc.’s potential upside is 94.86% and its average target price is $1.5. Based on the results delivered earlier, Sunesis Pharmaceuticals Inc. is looking more favorable than Conatus Pharmaceuticals Inc., analysts view.

Institutional & Insider Ownership

Institutional investors owned 50.1% of Sunesis Pharmaceuticals Inc. shares and 25% of Conatus Pharmaceuticals Inc. shares. Sunesis Pharmaceuticals Inc.’s share owned by insiders are 0.2%. Competitively, insiders own roughly 3.34% of Conatus Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sunesis Pharmaceuticals Inc. -15.38% -10.37% 128.3% -12.95% -54.34% 191.08%
Conatus Pharmaceuticals Inc. -0.73% 13.99% -55.73% -82.92% -76.56% -47.28%

For the past year Sunesis Pharmaceuticals Inc. has 191.08% stronger performance while Conatus Pharmaceuticals Inc. has -47.28% weaker performance.

Summary

Conatus Pharmaceuticals Inc. beats on 6 of the 11 factors Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein BrutonÂ’s tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.